ArticleViruses2021
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.International journal of molecular sciences · 2024Article
- Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.Heliyon · 2024Article
- HIV and SARS-CoV-2 Pathogenesis and Vaccine Development.Viruses · 2022Article
- High-Throughput Assay for Identifying Diverse Antagonists of the Binding Interaction between the ACE2 Receptor and the Dynamic Spike Proteins of SARS-CoV-2.ACS infectious diseases · 2022Article
- A Molecular Mechanics Energy Partitioning Software for Biomolecular Systems.Molecules (Basel, Switzerland) · 2022Article
- Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.Antimicrobial agents and chemotherapy · 2022Article
- Cell and Animal Models for SARS-CoV-2 Research.Viruses · 2022Review
- New insights into the catalytic mechanism of the SARS-CoV-2 main protease: an ONIOM QM/MM approach.Molecular diversity · 2022Article
- Structural, energetic and lipophilic analysis of SARS-CoV-2 non-structural protein 9 (NSP9).Scientific reports · 2021Article
- Amino Alcohols from Eugenol as Potential Semisynthetic Insecticides: Chemical, Biological, and Computational Insights.Molecules (Basel, Switzerland) · 2021Article
- New carvacrol and thymol derivatives as potential insecticides: synthesis, biological activity, computational studies and nanoencapsulation.RSC advances · 2021Article
- How Physical Factors Coordinate Virus Infection: A Perspective From Mechanobiology.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Productive SARS-CoV-2 infection relies on viral entry into cells expressing angiotensin-converting enzyme 2 (ACE2). Indeed, viral entry into cells is mostly mediated by the early interaction between the viral spike protein S and its ACE2 receptor. The S/ACE2 complex is, thus, the first contact point between the incoming virus and its cellular target; consequently, it has been considered an attractive therapeutic target. To further characterize this interaction and the cellular processes engaged in the entry step of the virus, we set up various
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.